L3VLUP
ProSign in

PHVS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PHVSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PHVS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterPHVSVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 20214 holders, $74m31 holders, $15.4bn
Q2 20212 holders, $45m30 holders, $12.7bn
Q3 20211 holders, $41m35 holders, $10.1bn
Q4 20211 holders, $39m28 holders, $12.4bn
Q1 20221 holders, $46m23 holders, $16.1bn
Q2 20221 holders, $55m25 holders, $18.1bn
Q3 20221 holders, $20m22 holders, $18.4bn
Q4 20221 holders, $36m28 holders, $18.4bn
Q1 20231 holders, $25m26 holders, $21.4bn
Q2 20231 holders, $51m27 holders, $24.7bn
Q3 20231 holders, $67m33 holders, $24.3bn
Q4 20232 holders, $105m32 holders, $28.6bn
Q1 20241 holders, $84m31 holders, $29.8bn
Q2 20241 holders, $69m29 holders, $33.4bn
Q3 20241 holders, $68m27 holders, $33.5bn
Q4 20241 holders, $70m26 holders, $28.5bn
Q1 20251 holders, $57m21 holders, $35.4bn
Q2 20251 holders, $64m21 holders, $32.3bn
Q3 20251 holders, $91m22 holders, $25.9bn
Q4 20251 holders, $101m26 holders, $31.8bn
Q1 20261 holders, $103m25 holders, $31.8bn
Q2 20263 holders, $185m26 holders, $34.6bn
PHVS

Pharvaris N V

Holders
1
Reported value
$70m
Buyers
0
Sellers
0

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only PHVS (1)

Viking Global Investors LP

Only VRTX (26)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →